Members of transcription factor (TF) families, i.e. paralogous TFs, are oftentimes reported to have identical DNA-binding motifs, despite the fact that they perform distinct regulatory functions in the cell. Differential genomic targeting by paralogous TFs is generally assumed to be due to interactions with protein cofactors or the chromatin environment. Contrary to previous assumptions, we find that paralogous TFs have different intrinsic preferences for DNA, not captured by current motif models, and these differences partly explain differential genomic binding and functional specificity. Our finding was possible due to a unique combination of carefully designed high-throughput assays and rigorous computation modeling, integrated into a unified framework called iMADS. We used iMADS to quantify, model, and analyze specificity differences between 11 paralogous TFs from 4 distinct human TF families. Our finding of differential specificity between closely related TFs has important implications for the interpretation of the regulatory effects of non-coding genetic variants.
INTRODUCTION
Transcription factors (TFs) interact with DNA in a sequence-specific manner, and these interactions represent a key mechanism in the regulation of gene expression. In eukaryotes, most TF-coding genes have undergone gene duplication and divergence during evolution [8] [9] [10] [11] [12] [13] [14] [15] , resulting in many TFs having highly similar DNA binding domains and recognizing similar DNA sequence motifs. TFs with such properties that also belong to the same species are called 'paralogous' TFs. Some paralogous TFs have partly (or completely) redundant functions. Most mammalian TFs, however, have evolved regulatory functions that are distinct from their paralogs in the cell 10, 11, 16 . For example, in the Class I subfamily of ETS transcription factors [18] [19] [20] , protein Ets1 is involved in B-cell, T-cell and natural killer cell differentiation [21] [22] [23] [24] [25] [26] , while protein Elk1 regulates chromatin remodeling, serum response factordependent transcription, and neuronal differentiation 21, [27] [28] [29] [30] [31] [32] [33] . In general, paralogous TFs accomplish a wide variety of independent or complementary molecular functions to regulate cellular phenotypes.
Many methods have been developed to learn TF-DNA binding specificity models from high-throughput in vivo and in vitro experimental data, ranging from simple position weight matrices (PWMs) to stateof-art deep learning models [34] [35] [36] [37] [38] [39] [40] . According to these models, paralogous TFs, especially the ones with high amino acid identity in their DNA-binding domains, tend to have indistinguishable DNA-binding specificities 34 . As an important consequence, this restricts the inference of TF-DNA interactions to family-wide predictions, rather than predictions for individual family members.
Since paralogous TFs are often co-expressed in the same cells but they perform different, sometimes even opposite, biological functions, being able to identify genomic binding sites of individual TF family members is critical. For example, while c-Myc is a well-known oncoprotein that promotes transcriptional amplification, its co-expressed paralog Mad is a tumor suppressor and represses gene expression [41] [42] [43] . Currently, little is known about the mechanisms that explain the differential genomic targets of paralogous TFs. Furthermore, when analyzing in vivo TF-DNA binding data, such as data from chromatin immunoprecipitation coupled with sequencing (ChIP-seq) assays 44 , many genomic studies do not even take into account the presence of paralogous TFs, or the fact TF family members present in a cell are likely to influence each other's binding to the genome. Overall, given that the most mammalian TFs are part of large protein families with multiple paralogs expressed at the same time, it is surprising how little we know about how paralogous TFs achieve their unique specificities in the cell.
Here, we show that despite having similar DNA-binding domains, paralogous TFs have different intrinsic DNA-binding preferences and this explains, in part, their differential in vivo binding and functional specificity. We focus on closely related TFs reported to have indistinguishable DNA-binding motifs, but distinct sets of targets in vivo. We design custom DNA libraries containing putative TF binding sites in their native genomic sequence context, and we use in vitro genomic-context proteinbinding microarray (gcPBM) assays 45 to quantitatively measure binding of each TF to the genomic sequences in our custom library. The quantitative, high-throughput gcPBM measurements revealed extensive differences in binding specificity between most pairs of paralogous TFs tested in our study. Most differences are concentrated in the medium and low affinity ranges, which explains why there were missed by previous DNA-binding data and models (see Discussion). We emphasize that the differences observed in our study are due to the intrinsic DNA recognition properties of the TFs, because our gcPBM assays measure binding of purified TF proteins to naked DNA sequences. Importantly, though, the differences we identified in vitro help explain, in part, the differential in vivo binding profiles of paralogous TFs.
To quantify the differences in specificity between TF paralogs, we developed an innovative approach that combines binding data for paralogous TFs with data from replicate experiments to derive weighted least square regression models of differential specificity. We integrate our high-throughput data and computational models into a general framework called iMADS (integrative Modeling and Analysis of Differential Specificity), which we provide as a publicly available web tool (http://imads.genome.duke.edu). Using iMADS data and models, we show that genomic sites differentially preferred by TF paralogs have different sequence features and DNA shape profiles, and they are involved in distinct biological functions. Finally, applying iMADS models of differential specificity to the analysis of genetic variants provides novel insights into TF binding changes due to cancer somatic mutations.
RESULTS

Closely related paralogous TFs bind differently to their genomic target sites in vitro
Paralogous TFs have similar DNA-binding domains (DBDs). However, their DBDs are not identical, and the amino acid sequences outside the DBD region are quite different. We hypothesized that these differences in protein sequence could lead to differences in DNA-binding specificity. To test this hypothesis, we focused on 11 closely related human TFs from 4 distinct structural families: basic helix-loop-helix (bHLH), E26 transformation-specific (ETS), E2 factor (E2F), and Runt-related transcription factors (RUNX). The factors were chosen based on: (i) availability of high-quality ChIPseq data showing both overlapping and unique in vivo genomic targets for the paralogous TFs 40, 46 , and (ii) previous reports that the paralogous TFs have identical binding specificities 20, 34, 37, 47, 48 .
Focusing on putative genomic target sites in their native DNA sequence context, we asked whether paralogous TFs have identical DNA-binding preferences, as expected from their indistinguishable position weight matrix (PWM) models trained on either in vitro (Fig. 1A) or in vivo ( Supplementary  Fig. 1 ) data. In vitro PWMs for human TFs are typically derived from high-resolution binding data for a large set of artificial or randomized DNA sequences (e.g. universal PBM 49 or SELEX-seq 38 data), while in vivo PWMs are derived from low-resolution data on binding to genomic DNA (e.g. ChIP-seq 44 data). Our experimental approach, using gcPBM assays, is innovative in that we measure TF binding to genomic DNA sequences, i.e. sequences that the TFs also encounter in the cell, but at highresolution and in a controlled environment. Thus, we take advantage of critical aspects of both in vitro and in vivo approaches.
The gcPBM assay measures the level of binding of a TF to tens of thousands of genomic regions simultaneously. Briefly, double-stranded DNA molecules attached to a glass slide (microarray) are incubated with an epitope-tagged TF. To detect the amount of TF bound to each DNA spot, the microarray is labeled with a fluorophore-conjugated antibody specific to the epitope tag, and scanned using a standard microarray scanner. The gcPBM protocol is similar to the universal PBM protocol of Berger and Bulyk 50 . The critical difference between the widely-used universal PBMs 20, [34] [35] [36] 49 and the gcPBM assays in our study is in the design of the DNA library synthesized on the array. Universal PBMs use artificial sequences that cover all possible 10-bp DNA sites. Thus, they provide a comprehensive view of TF binding specificity for short sequences, but miss important information about the influence of flanking regions, which can significantly affect genomic binding 45 . In addition, universal PBMs suffer from significant spatial and location bias, due to the position of a probe on the microarray and the position of a TF binding site on the probe, respectively 49, 51 . In comparison, gcPBM libraries contain ~30,000 genomic sequences, 36-bp long, centered on putative binding sites for particular TFs or TF families (Supplementary Fig. 2A ). Each sequence is represented six times in DNA spots randomly distributed across the array, and we use median values over replicate spots as TF binding specificity measurements. Our gcPBM libraries are carefully designed to: 1) capture the influence of flanking regions on TF-DNA binding by centering probes on the putative TF binding sites; 2) minimize spatial bias by using median values over replicates spots; and 3) eliminate positional bias in the data by fixing the position of TF binding sites within probes. These critical characteristics of the experimental design lead to TF binding measurements that are highly reproducible, cover a wide range of binding affinities, and are in great agreement with independent binding affinity data ( Supplementary Fig. 2B,C) . In addition, as shown in our proof-of-concept study 45 , gcPBM measurements are sensitive enough to capture differences in specificity among related TFs.
To directly compare the binding specificities of TFs within each family, we designed family-specific DNA libraries containing putative binding sites in their native genomic context, and we used gcPBM assays to test in vitro binding of each family member to the selected genomic sites (Fig. 1B) . The 11 TFs tested in our study are: c-Myc (henceforth referred to as Myc), Max, and Mxd1 (or Mad1, henceforth referred to as Mad) from the bHLH family; Ets1, Elk1, and Gabpa from the ETS family; E2f1, E2f3, and E2f4 from the E2F family; and Runx1 and Runx2 from the RUNX family. For all 11 TFs, the gcPBM assays provided quantitative measurements of in vitro specificity for tens of thousands of genomic sites. The vast majority of these sites were bound with affinities higher than negative controls, indicating that the selected genomic targets are specifically bound by the TFs in our study.
We analyzed the gcPBM data and, surprisingly, for most pairs of paralogous TFs we found extensive differences in their in vitro binding specificity for genomic sites, more than expected due to experimental noise (Fig. 1C,D) . The way in which paralogous TFs differ is different for each family (Fig. 1C , top panels). bHLH proteins Mad and Myc bind similarly to many of their putative genomic targets, but there is a subset of sites bound with higher affinity by Myc than by Mad. ETS proteins Elk1 and Ets1 bind similarly to their high affinity genomic sites, but they diverge in specificity for medium and low affinity sites. E2F proteins E2f1 an E2f4 show differences across the entire affinity range, but mostly in the medium affinity sites. We note that although single gcPBM assays do not directly provide affinity measurements, the DNA-binding intensities measured by PBM do correlate very well with independently measured affinities (Supplementary Fig. 2C ). To our knowledge, our data are the first to show that these closely related TFs have different intrinsic specificities for their genomic target sites.
The pair of paralogous TFs most similar to each other is Runx1 vs. Runx2 (rightmost panels in Fig. 1C,D) . These factors act in different tissue types and are not typically co-expressed under normal cellular conditions [52] [53] [54] [55] [56] [57] . Thus, their differential in vivo binding may be regulated through differential chromatin accessibility or different protein cofactors expressed in each cell type. The high similarity between the binding specificities of Runx1 and Runx2 is also not surprising given that their DNAbinding domains (DBDs) are 91% identical. Interestingly, considering all 11 pairs of paralogous TFs in our study, we did not see a correlation between DBD amino acid identity and similarity in DNA binding specificity (R 2 =0.01, Supplementary Fig. 3 ), indicating that amino acid identity might not be predictive for whether paralogous TFs prefer similar DNA target sites.
Overall, our gcPBM data show that most TF pairs converge in their specificity for high affinity sites, but bind differently to low and medium sites. This explains why many previous studies reported indistinguishable PWMs for these paralogous TFs 34, 37 : PWMs are best at capturing high affinity sites 58 , which are indeed bound the same way by the paralogous factors. However, medium and low affinity TF binding sites, which can play important regulatory roles in the cell [58] [59] [60] [61] [62] , are oftentimes bound differently by TF family members, and may contribute to the differential genomic binding and functional specificity of closely-related TFs. Therefore, we emphasize that quantitative measurements of TF binding over a broad affinity range, such as measurements provided by gcPBM assays, are critical for comparisons of paralogous TFs.
Generalizing TF binding specificities beyond the gcPBM measurements
In a single gcPBM experiment we can test up to ~30,000 genomic sites. However, a library of this size is still not sufficient to cover all putative genomic targets of human TFs. To generalize our TF-DNA binding measurements beyond the genomic sites tested on gcPBMs, we used ε-support vector regression (ε-SVR) 63 to train positional k-mer regression models for all 11 TFs in our study. We used binary features to encode the identities of mononucleotides (1-mers), dinucleotides (2-mers), and trinucleotides (3-mers) at each position in the TF binding sites and their flanking regions ( Supplementary Fig. 4 ), similar to our previous work 45, [64] [65] [66] . A novel feature of the approach used in this work is that we build a 'core-stratified' SVR model for each TF, i.e. a separate SVR model is trained and tested for each 'core motif' of the TF ( Fig. 2A) . Core motifs are defined based on gcPBM data and, if available, based on prior structural knowledge about the interactions between DNA and TFs from each family (Methods). Core motifs are short (4-6bp) and capture the region within TF binding sites that has little degeneracy, likely because of direct interactions with residues in the DNAbinding domain of the TF (Fig. 2B,C) . For example, for the bHLH transcription factor Mad, the corestratified SVR model is based on five E-box or E-box-like cores (Fig. 2D) . For all 11 TFs in our study, the core-stratified SVR models achieved high prediction accuracy (R 2 =0.82-0.96) on independent, held-out data, indicating that the models accurately capture TF-DNA binding specificity (Fig. 2E, Supplementary Fig. 5, Supplementary Table 1 ). All validations were performed using embedded 5-fold cross-validation tests (Methods). As baseline, we applied a nearest neighbor approach to the same folds as the core-stratified SVR. The nearest neighbor models had significantly lower accuracy, as expected (Supplementary Fig. 6 ). Given the high accuracy of our core-stratified SVR models, we can confidently use these models to predict TF binding to DNA sites not included in our gcPBM libraries. Importantly, we note that that core-stratified SVR models have prediction accuracy close to replicate experiments. Thus, while more complex models of specificity can be derived from our high quality gcPBM data, we do not expect such models to show large improvements in prediction accuracy compared to our core-stratified SVR models. Our simple, corestratified approach is motivated by our observation that for different core motifs the sequences flanking the core contribute differently to the binding affinity ( Supplementary Fig. 7A,B) . To our knowledge, such interactions between the core TF binding motifs and the flanking base pairs have not been previously characterized in the literature. Training a separate SVR model for each core allows us to take into account the dependencies between the core motif and the flanking regions without resorting to complex computational models.
Modeling the differential DNA-binding specificity of paralogous TFs
Our gcPBM data revealed clear differences in the binding preferences of paralogous TFs for putative genomic target sites (Fig. 1) . As with all high-throughput technologies that do not measure DNAbinding affinities directly, the binding measurements obtained by gcPBM are not directly comparable between TFs (one reason being that the samples used in experiments may have different concentrations of active TF protein). To address this shortcoming and perform a robust comparison between paralogous TFs, we developed and implemented a weighted regression approach (Fig. 3) .
As described below, this approach allows us to quantify specificity differences and to identify genomic sites differentially preferred by paralogous TFs.
Briefly, we apply weighted least square regression (WLSR) to fit the gcPBM data for two paralogous TFs (Fig. 3A) , as well as replicate gcPBM data sets (Fig. 3B) . Next, we integrate information about the variance learned from replicate data sets into the weighted regression model for the paralogous TFs, in order to calculate a '99% prediction band' that comprises all genomic sites bound similarly by the two factors, i.e. sites for which the difference in binding specificity between TF1 and TF2 is within the noise expected for replicate experiments. Intuitively, one can interpret the 99% prediction band as follows: if TF1 and TF2 were replicates, then we would expect 99% of their target sites to fall within the prediction band. We consider the sites outside the prediction band as differentially preferred by TF1 versus TF2, and for each such site we compute a quantitative 'preference score' (Fig. 3C , Methods). We used our WLSR-based approach to compare all pairs of paralogous TFs in our study (Supplementary Fig. 8 ). For all TF pairs except Runx1 vs Runx2, we found that between 15% and 55% of the genomic sites tested by gcPBM were differentially preferred (Fig. 3D, Supplementary  Table 2 ). Thus, our WLSR approach allows us to identify, for the first time, genomic sites differentially preferred by paralogous TFs, i.e. sites for which the difference in binding between TFs is larger than the variability observed in replicate experiments.
To facilitate the use of our WLSR models of differential specificity between paralogous TFs, as well as our core-stratified SVR models of binding specificity for individual TFs, we developed the iMADS web server: http://imads.genome.duke.edu. The web server allows users to apply our models for each TF or TF pair to make predictions on any genomic or custom DNA sequence.
Sequence and structural characteristics of genomic sites differentially preferred by paralogous TFs
We analyzed the differentially preferred genomic sites to determine sequence and structural features preferred by each TF. We found that the observed specificity differences between paralogous TFs are due both to the core binding site and the flanking regions, demonstrating the importance of including genomic flanks when measuring and comparing in vitro binding of these TFs. To identify significant differences in core and flanking preferences between TF1 and TF2, we applied the Mann-Whitney Utest to determine, for each core sequence and each 1-mer, 2-mer, and 3-mer feature in the flanking regions, whether the sequence feature is enriched in the set of TF1-preferred or TF2-preferred genomic sites. We report all p-values, adjusted using the Benjamini-Hochberg procedure, in Supplementary Table 3 .
Core motifs play critical roles in TF-DNA recognition through direct interactions, mostly hydrogen bonds, between the proteins and DNA. This direct readout mechanism is a major contributor to the binding specificity of TFs 67 . In particular, direct readout in the core binding region is known to be different for different TF families 67 . Our results show that even within TF families, the core binding region can contribute to differences in binding specificity between factors (Fig. 4A , Supplementary Fig. 9A,B) . For example, within the ETS family, the GGAT core is strongly preferred by Ets1 compared to both Elk1 (p=3.5x10 -99 , Fig. 4A ) and Gabpa (p=1.8x10 -202 , Supplementary Table 3) .
Focusing on sequence features in the flanking regions, we identified numerous 1-mer, 2-mer, and 3-mer features differentially preferred by paralogous TFs (Fig. 4B, Supplementary Fig. 9A ,B, Supplementary Table 3) . For example, for the GGAA core bound by ETS factors, we found that C immediately downstream of the core is strongly preferred by Elk1, while CA immediately upstream of the core is strongly preferred by Ets1 (Fig. 4B) . The differential preferences of paralogous TFs for flanking sequence features highlight the important role of genomic sequence context in establishing differential DNA binding between TF family members.
Flanking regions are likely contributing to TF-DNA binding specificity through indirect (i.e. shape) readout mechanisms. Using DNAshape 68 predictions of minor groove width, roll, propeller twist, and helix twist, we found that paralogous TFs differ significantly in their preference for certain DNA shape features, especially for minor groove width and roll (Fig. 4C, Supplementary Fig. 9C ,D, Supplementary Table 4 ). These findings are in agreement with previous hypotheses that DNA shape readout is often exploited to distinguish between TF family members 67 . Our data and models provide, for the first time, a way to comprehensively study the differences in DNA shape profiles preferred by paralogous TFs. 
Differential in vitro specificity partly explains differential in vivo binding and functional specificity of paralogous TFs
To test whether the differences in intrinsic binding specificity between paralogous TFs, as observed in our gcPBM data, are relevant for differential in vivo binding, we applied iMADS models to make predictions of specificity and differential specificity on ChIP-seq peaks for Mad and Myc from H1SC cells, Elk1 and Ets1 from K562 cells, and E2f1 and E2f4 in K562 cells 46 . We selected these data sets because they were not included in the gcPBM design, and thus are completely independent of our training data. For each TF pair, we processed the ChIP-seq data to identify peaks for each TF, we merged the two lists of peaks, and for each peak we computed the natural logarithm of the ratio between TF1 and TF2 ChIP-seq signals (Methods). We then scanned the peak regions and used iMADS models to predict differential binding of TF1 vs. TF2 (e.g. Fig. 5A ). To test whether the binding preferences captured by iMADS are relevant for the differential in vivo binding of paralogous TFs, we first performed a direct comparison between iMADS preference scores and differential ChIP-seq signal, computed for all peaks. As shown in Fig. 5B-D 82, 83 , etc. These biases can lead to false positive and false negative peaks, and they also significantly affect any quantitative estimates of in vivo TF binding levels derived from ChIP-seq data in ways that we do not understand well enough to correct 75 . It was also not surprising to find a lower correlation for the ETS proteins, compared to the bHLH and E2F proteins, given the low quality of the ChIP-seq data for Ets1 ( Fig. 5E-G; Supplementary Fig. 10 ). Next, we binned the ChIP-seq data into 10 bins of equal size, after sorting the peaks in increasing order of the log ratio of TF1 vs. TF2 ChIP signal. We found significant differences between the distributions of iMADS preference scores in different bins, with higher iMADS scores corresponding, in general, to bins with higher log ratio of TF1 vs. TF2 ChIP signal (Fig. 5B-D , right panels). This was especially true for proteins with high-quality ChIP-seq data (Mad vs. Myc, and E2f1 vs. E2f4), as shown in Fig. 5B-C . Binning the ChIP-seq data averages out experimental noise and biases inherent to ChIP data sets 69-78, 82, 83 ; at the same time, binning may average out important (although yet unknown) biological signals. The technical challenges of current ChIP-seq assays prevent a reliable quantification of how much of the iMADS variation in each bin is due to limitations of the in vivo data versus potential biological factors present in the cellular environment but missing in our in vitro system (see Discussion) .
To further analyze the relationship between TF binding in vitro and in vivo, we performed receiver operating characteristic (ROC) curve analyses, an approach that is widely used to evaluate the predictive power of DNA binding models with respect to in vivo ChIP-seq data 36, 39, [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] . Briefly, we aimed to evaluate how well our iMADS models of differential specificity can distinguish between TF1-preferred and TF2-preferred ChIP-seq peaks, defined as the top N% and bottom N% of peaks, respectively, sorted according to log ratio of ChIP signals (Fig. 5H) . We found that our iMADS models perform remarkably well. For bHLH proteins Mad vs. Myc, the iMADS model achieved areas under the ROC curve (AUCs) of 0.69-0.77, depending on the fraction of peaks chosen for the classification test (top and bottom 5%-30% of peaks, Fig. 5I ). In addition, the performance of iMADS models was superior to that of PWM models trained on either in vitro or in vivo data. In our comparisons we used in vitro PWMs trained on the same gcPBM data as the iMADS models. For the in vivo-derived PWMs, we used models trained on the same ChIP-seq data sets used for testing, thus giving in vivo PWMs an important advantage over the other models (see Methods). Nevertheless, our iMADS models of differential specificity performed best (Fig 5I) , which is impressive given that they were trained on independent data and using independent genomic sequences. The performance of iMADS models Supplementary Table 5 . The full data sets (3,726 peaks for bHLH proteins, 13,004 peaks for E2F proteins, and 2,208 peaks for ETS proteins) were used to assess the correlations, to compute the best fit lines (shown in grey) and to compute the bins. (E-G) Pearson correlation coefficients between the ChIP-seq pileup signals computed from replicate ChIP-seq data sets. All data sets used in this analysis show good correlation, except for the Ets1 ChIP-seq data. Additional analyses of ChIP-seq data quality, performed using the ENCODE IDR 17 pipeline, are shown in Supplementary  Fig. 10 . (H) ChIP-seq data for Mad and Myc, with peaks sorted in decreasing order of the log ratio of Mad vs. Myc signal. Regions of 1,000 bp centered at the peak summits are shown. The data can be used to identify 'Mad-preferred' and 'Mycpreferred' peaks, selected as the top and bottom N% of peaks, respectively. For different values of N, we tested how well iMADS models can distinguish between the peaks preferred by each TF. (I) Receiver operating characteristic (ROC) curves showing the performance of iMADS models of differential specificity, as well as PWM models trained on in vitro or in vivo data, in distinguishing Mad-preferred from Myc-preferred peaks. In vitro PWMs were derived from the same gcPBM data used to train iMADS preference models. In vivo PWMs were trained on the ChIP-seq data sets used for testing; thus, they are given an advantage over the other models. was (Fig. 5J) . Even in the case of ETS proteins, which have poorer quality ChIP-seq data, the performance of our iMADS models (trained on independent data) was comparable to the performance of in vivo motifs (trained on the ChIP-seq data itself), especially when focusing only on the top vs. bottom 5-10% of the peaks (Fig. 5K) . Thus, our results show the in vitro-derived iMADS models of differential specificity have significant predictive power in vivo.
Not surprisingly, we found that the correlation between iMADS preferences scores and differential ChIP-seq data is lower for TFs with low-quality ChIP-seq data, such as the ETS protein Ets1 (Fig. 5G) . In such cases, since the ratios of ChIP-seq signal contain very little information, an alternative way to analyze in vivo binding is to focus only on the high-confidence peak regions that are unique to each TF. Such an analysis is presented in Supplementary Fig. 11 , where we show that Elk1-unique peaks (i.e. genomic targets bound only by Elk1) contain sites with larger Elk1 preference scores, while Ets1-unique peaks contain sites with larger Ets1 preference scores. Thus, these results show that the differential specificity observed in vitro by gcPBM, and modeled using our iMADS framework, partly explains the differential in vivo genomic binding of paralogous TFs.
Paralogous TFs may achieve functional specificity through their differential DNA-binding specificity.
To test this hypothesis, we focused on the genomic sequences in gcPBM data that are differentially preferred by paralogous TFs, and we compared the biological functions of genes in the neighborhood of these genomic binding sites. As shown in Supplementary Fig. 12 for the example of Elk1 and Ets1, we successfully recovered different gene ontology (GO) terms that are enriched for genes associated with differentially preferred sites, with many of the terms reported previously in independent studies for the individual ETS factors 30, [95] [96] [97] [98] [99] [100] [101] . This suggests that sequences preferred differently by paralogous TFs in vitro are not only important for their differential genomic binding in vivo, but also help individual TFs achieve functional specificity in the cell.
To facilitate analysis of differential in vivo binding and functional specificity of paralogous TFs, users can easily access genome-wide predictions of TF binding specificity (from core-stratified SVR models; Supplementary Fig. 13A,B ) and differential specificity (from WLSR models; Supplementary Fig.  13C ) through the iMADS web server. In addition, users can focus on specific regions around genes, specify custom lists of genes or genomic coordinates to analyze, view predictions in the web server or in the UCSC genome browser, and make predictions of TF binding specificity and differential specificity for any DNA sequence of interest.
Disease-related genetic variants have differential effects on the specificity of paralogous TFs
Current studies of the effects of non-coding variants on TF-DNA binding focus on predicting changes in the DNA-binding specificity of individual TFs, assessed using simple PWMs [102] [103] [104] [105] or complex models 7, 39, 106 , but ignoring the fact that multiple paralogous factors are co-expressed in the cell and can influence each other's binding to the genome. The iMADS models allow us to test, for the first time, whether non-coding variants/mutations have differential effects on the binding specificity of paralogous TFs.
To illustrate how one can use our iMADS models and web server to analyze non-coding variants, we use as a case study the somatic mutation rs786205688, associated with malignant prostate cancer 2 .
The mutation resides in the POLK gene region, which is important for DNA damage repair, and it creates a binding site for the ETS family of TFs. According to current models, the newly created binding site has similar specificities for Ets1 and Elk1. However, according to the iMADS model of Elk1 versus Ets1 binding preference, the new site is highly preferred by Elk1, and bound only nonspecifically by Ets1, indicating that the functional effect of this mutation could be due to increased Elk1 binding (Fig. 6A) . This hypothesis is consistent with the fact that up-regulation and activation of Elk1 Figure 6 . Analyses of non-coding somatic mutations using iMADS models of specificity and differential specificity. (A) Example of iMADS predictions for variant rs786205688, a somatic mutation in the POLK gene region associated with malignant prostate cancer 2 . Plots show predicted ETS sites in a 300-bp genomic region centered on the somatic mutation (chr5:74893909). Binding sites (1), (2) , and (3) are present both in the wild-type (reference) and the mutant (tumor) sequences. Binding site (4) is created in the tumor by the somatic mutation. The color of the binding sites reflects the Elk1 vs. Ets1 preferences, as computed by iMADS. Scatterplots show the binding specificities and preferences of sites (4) and (2) (marked by stars) compared to the genomic sites tested by gcPBM in our study. (B) Scatterplot of the absolute change in Elk1 binding score compared to the absolute change in preference score of Elk1 vs. Ets1, for non-coding somatic mutations identified in melanoma cancer patients (ICGC data set SKCA-BR 3 ). Ovals highlight sets of mutations discussed in the main text. (C) Boxplot comparing the changes in preference score between non-coding somatic mutations identified in different types of tumors 3 , versus a control set of non-coding variants from the 1000 Genomes Project 6, 7 . The somatic variants were identified from either whole-genome (light orange bars) or whole-exome (dark orange bars) sequencing data from ICGC (Methods). The control variants (grey bar) were randomly selected among common variants with minor allele frequency > 0.01, as reported in the 1000 Genomes Project 6, 7 . For all tumor types, preferences changes are significantly larger for somatic mutations than for common variants: one-sided Mann-Whitney U test p-value < 2.2e -16. has been reported to associate with malignancy of prostate cancer, and inhibition of Elk1 has been proven effective on inhibiting growth of prostate cancer cells 33 . In Supplementary Fig. 14 we present the simple steps that users can follow to analyze non-coding variants, such as rs786205688, for their effect on binding of paralogous TFs. We note that the goal of such an analysis is not to conclusively identify a causal relationship between the variant and the phenotype, but to generate mechanistic hypotheses for follow-up analyses.
We also analyzed iMADS predictions for somatic mutations from melanoma whole-genome sequencing data 3 , to identify general patterns of TF preference change in disease-related mutations.
Interestingly, we found a subset of mutations (Fig. 6B, left oval) that have almost no change in Elk1 binding specificity, but large changes in Elk1 vs. Ets1 preference. Such mutations would be completely ignored by analyses focusing only on changes in Elk1 binding specificity. In addition, mutations with the largest change in Elk1 specificity tend to have small changes in preference score (Fig. 6B, right oval) . This was expected, as large changes in binding specificity will correspond to high affinity sites (in either wild-type or mutant sequences), which are bound similarly by the two TFs. Interestingly, we also found that mutations that maximize the change in Elk1 vs. Ets1 preference (Fig.  6B , top oval) are not the ones that maximize the change in Elk1 binding specificity. Thus, if one uses the change in Elk1 binding score to prioritize mutations, these mutations would not get high priority, although they could have large changes in Elk1 binding in vivo due to the change in preference relative to Ets1.
Next, we extended our analysis of non-coding somatic mutations to several tumor types with publicly available whole-genome or whole-exome sequencing data from the International Cancer Genome Consortium 3 . (We note that non-coding mutations in close proximity to coding regions can be identified from exome sequencing data.) We analyzed non-coding mutations from melanoma, breast cancer, liver cancer, pancreatic cancer, prostate cancer, and lymphoma, as well as a control set of common non-coding variants (Methods). We found that cancer mutations lead to significantly larger changes in Elk1-Ets1 preferences scores (Fig. 6C) , suggesting that changes in the relative preferences of paralogous TFs could have important phenotypic effects. Interestingly, the changes in Elk1 vs. Ets1 binding preference were much more pronounced in melanoma compared to other tumor types. A major mutagenic factor in melanoma is ultraviolet light, which causes pyrimidine dimers, a type of DNA damage that occurs between neighboring pyrimidine nucleotides. As a result, melanoma samples have a very high frequency of C>T mutations, particularly at CC and TC dinucleotides. Given the high specificity of ETS family proteins for TTCC/GGAA and ATCC/GGAT cores, it is perhaps not surprising that binding of this family of TFs is more likely to be affected in melanoma than other tumor types. Our iMADS models of differential specificity allow us, for the first time, to study the effects of non-coding somatic mutations on the genomic binding of individual TF family members, taking into account the fact that a particular TF can be affected either directly (by mutations that change its specificity) or indirectly (by mutations that change the specificity of competing TF family members). To our knowledge, iMADS is the only available tool that allows users to analyze changes in relative preferences of paralogous TFs due to genetic variation, and we expect it to provide important insights into the interpretation of disease-causing non-coding mutations.
DISCUSSION
DNA binding specificity is a fundamental characteristic of TFs. Nevertheless, the contribution of intrinsic sequence specificity to the differential in vivo binding of paralogous TFs is a largely unexplored area of research. Focusing on 11 paralogous TFs across 4 distinct protein families, we show that differences in intrinsic specificity, not captured by current DNA motifs model, can be critical for TF family members to distinguish between their genomic targets and achieve functional specificity in the cell. The integrated computational-experimental approach described in our study is general and can be applied to any pair of paralogous TFs.
Integrating quantitative measurements and modeling, as in our iMADS framework ( Supplementary  Fig. 15 ), is key to identifying and characterizing the differences between paralogous TFs. Most previous studies of TF-DNA binding focused on high affinity sites, which we find to be bound with similar specificities by paralogous TFs. For example, HT-SELEX/SELEX-seq assays 37, 38, 107 exponentially enrich for high affinity sites, which limits their ability to obtain quantitative measurements for medium and low affinity sites. Our gcPBM data clearly shows that medium and low affinity sites have important contributions to the differential binding of paralogous TFs, in agreement with previous studies recognizing the importance of such sites for TF-DNA binding in vitro and in vivo 20, 35 . In addition, a critical feature of our experimental approach is that we tested TF binding to DNA sites in their native genomic sequence context, but in a controlled environment where we can directly assess and compare the intrinsic specificities of TFs for DNA. As shown by our results (Fig. 3,  Supplementary Fig. 9 ), genomic sites differentially preferred by paralogous TFs have different sequence and shape features in their flanking regions. Importantly, we note that these contributions from the flanking regions are not due to cofactors or other influences, but to the intrinsic recognition properties of the paralogous factors.
Our results show that differences in intrinsic binding specificity between paralogous TFs have a significant contribution to differential in vivo binding (Fig. 5) . Currently, this contribution cannot be reliably quantified using existing in vivo ChIP-seq data, as it is well known that traditional ChIP-seq methodologies are not inherently quantitative 108 . The frequently poor affinity, specificity, and reproducibility of antibodies represent a major source of experimental error in ChIP-seq 109 ( Supplementary Fig. 16 ). In addition, technical biases due to formaldehyde crosslinking [70] [71] [72] [73] [74] [75] , highly expressed regions of the genome [79] [80] [81] , genome fragmentation and PCR amplification 82, 83 confound the true in vivo binding levels of paralogous TFs. When considering comparisons between ChIP-seq data sets, differences in experimental handling of the samples, as well as differential amplification prior to sequencer loading can also make direct ChIP-based comparisons problematic 109 . On the other hand, gcPBM assays provide direct measurements of TF binding, they have a simple design and few steps where technical biases could be introduced. But gcPBMs only capture DNA binding specificity coming directly from the protein, as the assays are performed using naked DNA and purified proteins. 'Intermediate' assays, such as sequencing-based assays that test TF binding to purified genomic DNA might be helpful, as they would have many of the same biases as ChIP-seq, but would lack any additional in vivo factors. Several modifications to traditional ChIP-seq protocols have also been proposed recently in order to allow quantitative comparisons between data sets [108] [109] [110] , primarily for histone proteins, by using spike-in controls. In addition, combining assays such as CUTandRUN 111 or ChEC-seq 112 (which alleviate some of the technical biases of ChIP-seq) with ChIP-exo 113 or ChIPnexus 114 (which improve the resolution of the in vivo data), may improve our ability to quantify the in vivo binding levels of human paralogous TFs in the future. Currently though, for human TF proteins, traditional ChIP-seq is still the technique used by individual labs and research consortia, including the ENCODE consortium that generated the data used in our study 46 . Nevertheless, despite the shortcomings of current in vivo data, our results provide compelling evidence that differential intrinsic specificity of paralogous TFs, reported and quantified for the first time in our study, is likely one of the mechanisms for achieving differential genomic targeting in the cell.
Our discovery of the differential binding specificity between closely related TFs has major implications for interpreting the effects of non-coding genetic variants and mutations. Some disease-causing mutations could significantly affect binding of a TF by changing its preference relative to other family members expressed in the same cells. To our knowledge, no previous studies of non-coding genetic variations takes into account the potential influence of competing TF family members. Our analysis of somatic non-coding mutations shows that mutations that maximize the change in preference between paralogous TFs are not those that maximize change in specificity for either TF. This suggests that focusing on changes in binding specificity for individual TFs, as in previous studies, has limited power in understanding the effects of non-coding mutations on TF binding.
Given that the most mammalian TFs are part of large protein families with multiple TF paralogs expressed at the same time, it is surprising how little we know about how paralogous TFs achieve their unique specificities in the cell. We acknowledge that in vivo binding of a TF is a result of many complicated factors, including not only the intrinsic DNA-binding specificity of that TF and its paralogs, but also the concentrations of the paralogous TFs, the presence and concentrations of co-factor proteins 107, [115] [116] [117] , the chromatin environment, etc. Our study takes an important first step in deciphering the molecular mechanisms of differential specificity in TF families, by identifying differences in intrinsic preferences between paralogous TFs and showing that these in vitro differences partially explain differential in vivo binding. We envision that more quantitative highthroughput technologies and computational models will be developed to gain a deeper understanding of the differential genomic binding and function of paralogous TFs.
METHODS [online]
Methods and associated references are available as Supplementary Material.
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